Hypoxic Signaling: Relation to Cancer Progression and Cancer Stem Cell Regulation
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 15 January 2025 | Viewed by 101
Special Issue Editor
Interests: breast cancer; prostate cancer; cancer stem cells; hypoxia and cancer; cell signaling; chemotherapy resistance; therapy resistance
Special Issue Information
Dear Colleagues,
The connection between hypoxia and pluripotent cells was made a long time ago by Dr. Shinya Yamanaka who discovered the essential factors needed for pluripotency induction in differentiated cells. All types of cancer contain cancer stem cells representing a small fraction of the bulk tumor, usually around 0.1 – 1% of the total cell number. These cancer stem cells have been shown to be dependent on the same pluripotency-inducing factors discovered by Yamanaka and to be affected by hypoxia. To make things more complicated, hypoxic signaling can be induced by more factors than just hypoxia. The main hypoxic signaling factors HIF-1α and HIF-2α are regulated by multiple pathways, even under normoxic conditions. The aim of this Special Issue is to highlight the different mechanisms regulating hypoxic signaling, i.e., HIF-1α and HIF-2α, and their relation to cancer stem cell regulation, cancer progression and treatment resistance.
Dr. Anders M. Ström
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HIF-1α
- HIF-2α
- cancer stem cells
- treatment resistance
